This funding opportunity supports early stage testing of pharmacologic or neuromodulatory device-based interventions for mental disorders. It requires an experimental therapeutics approach where clinical trials evaluate both the clinical effect and underlying mechanisms of the intervention. Studies must use protocol designs that adequately test the presumed mechanism of action, providing meaningful dose-dependent neurophysiological, clinical, or behavioral data.
Eligible applicants include a wide range of U.S. entities such as government bodies, nonprofits, for-profit organizations, small businesses, and institutions of higher education. Specific eligibility details are provided in the full announcement.
